Home / Stocks / Concord Biotech Limited
CONCORDBIO

Concord Biotech Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹556.4

Change

-4.6 (-0.82%)

Open

₹556.0

Prev. Close

₹561.0

Day High

₹561.0

Day Low

₹549.1

Volume Analysis

Traded

272,032

Delivered

158,269

Delivery %

58.18%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (34.0%)

Weaknesses (0)

No signal for this stock

Opportunities (1)

  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹573.8 ₹567.4 ₹561.9 ₹555.5 ₹550.0 ₹543.6 ₹538.1
Fibonacci ₹567.4 ₹562.85 ₹560.05 ₹555.5 ₹550.95 ₹548.15 ₹543.6
Camarilla ₹559.67 ₹558.58 ₹557.49 ₹555.5 ₹555.31 ₹554.22 ₹553.13

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-58.36%

1 Week

-7.54%

1 Month

-56.19%

3 Months

-64.59%

6 Months

-51.76%

1 Year

-61.37%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹112.4

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

15.23%

Net margin 23.85% × asset turnover 0.57x × equity multiplier 1.12x

Company Overview

Sector

Healthcare

Market Cap

₹12,146 Cr

P/E (TTM)

42.6

ROE

12.9%

Book Value

₹99.2

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.

TopFund Analysis

Concord Biotech Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 60/100. The strongest factor is Financial Strength (100/100), while Valuation (19/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (34.0%). FII holding has been rising.

TopFund Score — Fundamentals Quality

60/100 — Average

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

29

Valuation

19

Cash Flow

66

Corporate Governance

90

Momentum

28

Institutional Ownership

63

Business Quality

84

Risk & Volatility

25

Liquidity

80

From Screener.in

  • +Company has reduced debt.
  • +Company is almost debt free.
  • +Company has been maintaining a healthy dividend payout of 28.2%
  • −The company has delivered a poor sales growth of 11.3% over past five years.
  • −Company has high debtors of 159 days.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Concord Biotech allotted 10,46,16,204 bonus shares on November 4, 2026, in 1:1 ratio.

Transcript of Q2 - FY27 Earnings call held on October 28, 2026

Q2 and half-year FY27 earnings call recording hosted on company website.

Concord Biotech will attend a UBS non-deal roadshow in Singapore on 3-4 November 2026.

Press release - For the Second quarter and half year ended on September 30, 2026

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 262 241 319 216 310 244 430 204 247 278 326 257 309
Expenses + 147 135 187 135 176 146 241 143 159 179 208 175 205
Operating Profit 116 106 132 81 134 98 189 61 88 98 118 82 104
OPM % 44.0% 44.0% 41.0% 38.0% 43.0% 40.0% 44.0% 30.0% 36.0% 35.0% 36.0% 32.0% 34.0%
Other Income + 8 11 11 12 10 17 9 15 16 7 15 14 10
Interest 1 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 13 14 14 13 13 13 15 18 18 19 20 18 18
Profit before tax 110 103 129 80 130 101 184 59 86 86 114 78 95
Tax % 26.0% 25.0% 26.0% 25.0% 27.0% 25.0% 24.0% 25.0% 26.0% 26.0% 22.0% 26.0% 27.0%
Net Profit + 81 78 95 60 96 76 140 44 63 64 88 58 70
EPS in Rs 4 4 5 3 5 4 7 2 3 3 4 3 3
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 65 0 17 11 18 1 35 -5 -20 14 -24 26 25

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 239 276 340 436 512 616 713 853 1,017 1,200 1,055 1,170
Expenses + 133 145 212 256 308 289 443 509 585 694 687 768
Operating Profit 105 131 127 180 205 327 270 344 432 506 368 403
OPM % 44.0% 48.0% 37.0% 41.0% 40.0% 53.0% 38.0% 40.0% 42.0% 42.0% 35.0% 34.0%
Other Income + 11 8 36 17 32 14 23 37 37 44 52 46
Interest 1 0 1 1 1 1 6 5 3 1 1 0
Depreciation 10 10 18 19 21 28 50 54 54 54 74 75
Profit before tax 106 129 144 178 214 313 238 322 413 495 345 374
Tax % 34.0% 33.0% 30.0% 33.0% 21.0% 25.0% 26.0% 25.0% 25.0% 25.0% 25.0% —
Net Profit + 70 87 100 118 169 235 175 240 308 372 259 279
EPS in Rs 3 4 5 6 8 11 8 11 15 18 12 14
Dividend Payout % 22.0% 25.0% 0.0% 21.0% 22.0% 0.0% 3.0% 30.0% 30.0% 25.0% 30.0% —
Sales growth — 16 — 28 — 20 16 20 19 18 -12 4

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 268 329 585 673 761 990 1,094 1,280 1,516 1,802 2,007 2,065
Borrowings + 35 36 22 9 52 86 62 32 10 3 2 2
Other Liabilities + 55 74 69 71 118 97 147 192 164 219 212 249
Total Liabilities 367 448 685 763 941 1,183 1,313 1,514 1,701 2,034 2,232 2,327
Fixed Assets + 104 110 189 230 240 546 573 593 575 795 789 771
CWIP 19 70 3 19 141 18 74 173 211 51 79 112
Investments 42 43 151 229 199 141 74 137 246 335 491 533
Other Assets + 202 225 343 285 361 477 592 611 668 854 873 911
Total Assets 367 448 685 763 941 1,183 1,313 1,514 1,701 2,034 2,232 2,327
Equity Capital 9 9 10 10 10 10 10 10 10 10 10 10

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + — — 79 — 155 167 207 246 265 245 267
Cash from Investing Activity + — — -42 — -114 -195 -112 -158 -155 -160 -143
Cash from Financing Activity + — — -37 — -43 31 -100 -85 -99 -99 -113
Net Cash Flow — — 0 — -1 3 -4 3 12 -14 11
Free Cash Flow — — 79 — -1 -38 52 101 180 134 172
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit — — 101 — 100 74 99 92 85 70 100

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 44.08% → 44.09%
  Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026 Nov 2026
Public 41.03% 38.46% 37.95% 37.93% 37.41% 37.94% 38.32% 38.75% 38.9% 39.04% 37.68% 37.58%
Promoters 44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.09% 44.09%
FII 6.49% 7.11% 8.1% 8.33% 9.35% 9.1% 8.03% 7.58% 7.79% 7.53% 7.28% 7.33%
DII 8.41% 10.35% 9.89% 9.65% 9.16% 8.85% 9.55% 9.58% 9.22% 9.37% 10.95% 11.02%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Concord Biotech Limited (this stock) 12,146 42.6 5.86 12.9%
Metropolis Healthcare Ltd 11,711 50.7 7.13 13.6%
Rainbow Childrens Med Ltd 12,607 43.0 7.34 16.7%
Viyash Scientific Limited 11,285 46.6 3.56 7.39%
Akums Drugs And Pharma L 11,279 29.9 3.22 8.45%
Park Medi World Limited 11,039 43.1 5.12 16.8%
Marksans Pharma Limited 13,347 23.8 4.0 15.2%

Which Mutual Funds Hold Concord Biotech Limited?

Frequently Asked Questions about Concord Biotech Limited

Community Sentiment

What are other investors saying about Concord Biotech Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.